Literature DB >> 3400606

Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy.

R L Wilensky1, P Yudelman, A I Cohen, R D Fletcher, J Atkinson, R Virmani, W C Roberts.   

Abstract

Serial electrocardiographic changes in necropsy-proven idiopathic dilated cardiomyopathy are evaluated and a method of predicting heart weight using QRS amplitudes is described. In 34 patients with multiple electrocardiograms (mean 3/patient) progressive prolongation of PR interval (0.18 +/- 0.03 to 0.21 +/- 0.03, p less than 0.001) and QRS duration (0.10 +/- 0.02 to 0.13 +/- 0.03, p less than 0.0001) was noted. Progressive conduction abnormalities were common (82%). QTc interval and QRS- and T-wave axes did not change. In 50 patients with electrocardiograms within 60 days of death, total 12-lead QRS and V1 through V6 QRS amplitude correlated better with heart weight (r = 0.51, p less than 0.0001 and r = 0.55, p less than 0.0001) than the Estes-Romhilt score did. The mean total 12-lead QRS amplitude was 138 mm with a mean of 106 for V1 through V6. In 31 patients cardiac mass index was calculated and showed significant correlation with 12-lead and V1 through V6 QRS amplitudes (r = 0.68, p less than 0.0001 and r = 0.75, p less than 0.0001, respectively). The QRS amplitudes remained constant during the illness. By using total 12-lead QRS or frontal plane QRS amplitude, heart weight can be predicted as early as 2 years before death. Use of body surface area and QRS amplitude criteria increases the accuracy of heart weight prediction. Thus, progressive electrocardiographic changes are common in patients with idiopathic dilated cardiomyopathy and QRS amplitude criteria are more accurate in the prediction of left ventricular hypertrophy than standard criteria.

Entities:  

Mesh:

Year:  1988        PMID: 3400606     DOI: 10.1016/0002-9149(88)90225-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  23 in total

1.  Different effects of abnormal activation and myocardial disease on left ventricular ejection and filling times.

Authors:  Q Zhou; M Henein; A Coats; D Gibson
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

2.  Cardiac resynchronization therapy in pediatrics: emerging technologies for emerging indications.

Authors:  Edward K Rhee
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-10

3.  Influence of conduction time intervals on symptoms and exercise tolerance in patients with heart failure with left ventricular systolic dysfunction.

Authors:  A Champagne de Labriolle; C Leclercq; J C Daubert
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

4.  William Clifford Roberts, MD: an interview by W. Bruce Fye, MD.

Authors:  William C Roberts; W Bruce Fye
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-07

5.  Comparison of pharmacological treatment alone versus treatment combined with cardiac resynchronization therapy in patients over 75 years.

Authors:  Elena de la Cruz; Marcelino Cortés; Jerónimo Farré; Julia Palfy; Paloma Ávila; Ignacio Hernández; Angélica Romero; Juan Benezet; Juan Antonio Franco; Miguel Angel Navas; Jose Joel Hernandez; Sem Briongos; José M Rubio
Journal:  J Interv Card Electrophysiol       Date:  2015-02-17       Impact factor: 1.900

6.  Effect of multisite pacing on ventricular coordination.

Authors:  C Varma; P O'Callaghan; N G Mahon; K Hnatkova; W McKenna; A J Camm; E Rowland; S J D Brecker
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

Review 7.  Congestive heart failure treatment: the pacing approach.

Authors:  T J Dresing; A Natale
Journal:  Heart Fail Rev       Date:  2001-01       Impact factor: 4.214

Review 8.  Recent advances in the optimization of cardiac resynchronization therapy.

Authors:  Satish Chandraprakasam; Gina G Mentzer
Journal:  Curr Heart Fail Rep       Date:  2015-02

9.  QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure.

Authors:  L Bode-Schnurbus; D Böcker; M Block; R Gradaus; A Heinecke; G Breithardt; M Borggrefe
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 10.  Devices in the management of advanced, chronic heart failure.

Authors:  William T Abraham; Sakima A Smith
Journal:  Nat Rev Cardiol       Date:  2012-12-11       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.